Dailypharm Live Search Close

Difficulty expanding indications for antibody-drug conjugate

By Moon, sung-ho | translator Alice Kang

24.10.30 05:54:05

°¡³ª´Ù¶ó 0
Company gives up expanding Trodelvy¡¯s indication to urothelial cancer

Korea¡¯s LigaChem Biosciences¡¯ technology export gains attention¡¦underpinned by Padcev¡¯s success

Drug candidates that received much expectation as next-generation antibody-drug conjugates (ADCs) based on the success of Enhertu are on a struggling path to reimbursement in Korea.  

Although the companies aimed to expand the scope of coverage of their drugs based on their effectiveness in specific cancer types, the expectations damped somewhat due to the disappointing clinical research results.

Nevertheless, the domestic and international pharmaceutical and bio industries are attempting to develop new drugs by starting clinical research on the combined use of ADCs and immuno-oncology drugs.


The TROP-2 class of drugs has been receiving the most attention as the next

Moon, sung-ho(lib6983@dailypharm.com)
If you want to see the full article, please JOIN US (click)